

UK Antimicrobial Registry (UKAR): Expanding to Outpatients & Antifungals

Study Team: Rebecca Parr, Jisha Babu, Jonathan Lock, Jay Woods



Epidemiology Group – School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, UK

UK Antimicrobial Registry

- Drug registry looking at effectiveness and safety of recently licensed antimicrobials
- Recruitment ongoing, since May 2023
- Supports antimicrobial stewardship of new agents

Inclusion criteria	Exclusion criteria
1. Patient prescribed any eligible study drug.	1. Patient was aged <18yrs on the first day of prescription with study drug.
2. First prescription of the study drug was <60 days prior to recruitment.	
3. Person consenting (patient or proxy) able to understand the consent process.	

What's New?


- Now recruiting **outpatients**
- Now recruiting patients commencing **Rezafungin**
- No longer recruiting patients commencing Dalbavancin

Two papers in JAC – Antimicrobial Resistance

- 📌 An overview of the first 20 months of recruitment
- 📌 UKAR: Virtual Registry-an innovative surveillance approach for monitoring the real-world use and effectiveness of newly licensed antimicrobials in Scotland

Data, as of 09th April 2026

- **Recruitment centres:**
 - 55 sites actively recruiting participants
- **Overview:**
 - 1261 participants recruited
 - 12 of 13 study drugs represented
 - Most prescribed drug is dalbavancin (N=411)
- **Most frequently recorded infections:**
 - Lower respiratory tract infection (26%)
 - Systemic infections & conditions incl. Sepsis (17%)
 - Bone and Joint Infection (16%)



Study drugs	N (%)	Characteristics
GRAM-POSITIVE		
• Dalbavancin	411 (35%)	Median age 54yrs (range 42-69yrs) 63% male
• Ceftaroline	38 (3%)	
• Ceftobiprole	6 (<1%)	
• Delafloxacin	4 (<1%)	
• Oritavancin	1 (<1%)	
GRAM-NEGATIVE		
• Ceftazidime/avibactam	289 (24%)	Median age 62yrs (range 46-72yrs) 54% male
• Cefiderocol	202 (17%)	
• Ceftolozane/tazobactam	166 (14%)	
• Aztreonam/avibactam	21 (2%)	
• Imipenem/cilastatin/relebactam	36 (3%)	
• Meropenem/vaborbactam	14 (1%)	
• Eravacycline	1 (<1%)	
• Cefepime/enmetazobactam	-	

N = number of times a study drug is used as the first treatment for a participant

For further information,
or to sign up:

abdn.ac.uk/ukar

